Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing mitochondria

A composition and mitochondrial technology, which can be used in drug combinations, medical preparations containing active ingredients, drug delivery, etc., and can solve problems such as adverse side effects, limited therapeutic scope, and no breakthrough therapeutic agents have yet been developed.

Inactive Publication Date: 2019-07-16
PAEAN BIOTECH
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, breakthrough therapeutics have not been developed due to issues such as limited therapeutic range and occurrence of adverse side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing mitochondria
  • Pharmaceutical composition containing mitochondria
  • Pharmaceutical composition containing mitochondria

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0108] Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for easier understanding of the present invention, and the present invention is not limited by the following examples.

[0109] I. Confirmation of the effect of mitochondria and cells containing exogenous mitochondria in the treatment of muscle diseases

Embodiment 1

[0110] Example 1. Establishment of Muscle Atrophy Animal Model and Measurement of Body Weight Change

[0111] 5-week-old female SD rats as experimental animals were purchased from Oriental Bio Co., Ltd. (Seoul, Korea). Rats were acclimated in the clean area of ​​the CHA University Laboratory Animal Center. During the acclimation period, the rats' environment was maintained on a 12-h light / dark cycle at room temperature of 23 ± 2 °C and humidity of 40 to 60%. After 7 days of such an acclimation period, experiments were performed on the rats.

[0112] To induce muscle atrophy, dexamethasone was administered intraperitoneally to rats at a dose of 5 mg / kg for 5 days. The rats were weighed every day, and it was confirmed that the weight of the dexamethasone-treated group on the 5th day of dexamethasone administration decreased by about 30% compared with the normal group ( figure 1 ).

Embodiment 2

[0113] Example 2. Preparation of mitochondria for transplantation

[0114] As donor cells for mitochondria, the rat skeletal muscle-derived cell line L6 (CRL1458, ATCC, Manassas, Virginia, USA) was cultured, and the resulting cells were stained with a mitochondria-specific marker (Mitotracker CMXRosRed) .

[0115] To extract mitochondria, measure the number of cells using a hemocytometer to recover approximately 2 × 10 7 cells / ml of cells. The cells were then subjected to a first centrifugation at 350 x g for 10 minutes at a temperature of about 4°C, and the resulting pellet was recovered and resuspended in buffer solution and then homogenized. The pharmaceutical composition containing the pellet was subjected to a second centrifugation at 1,100 xg for 3 minutes at a temperature of about 4°C to obtain a supernatant. The supernatant was then subjected to a third centrifugation at 12,000 xg for 15 minutes at about 4°C to isolate mitochondria from the cells.

[0116] To ident...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, therebyenabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamentalprevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.

Description

technical field [0001] The present invention relates to pharmaceutical compositions comprising mitochondria. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating muscle disease or ischemic disease, which contains mitochondria as an active ingredient. [0002] Background of the Invention [0003] Mitochondria are organelles essential for the survival of eukaryotic cells, and they are involved in the synthesis and regulation of adenosine triphosphate (ATP), which is used as an energy source. Mitochondria are involved in various metabolic pathways in the body, such as cell signaling, cell differentiation and cell death, as well as control of the cell cycle and cell growth. [0004] Thus, damage to mitochondria can lead to a variety of diseases, and most known mitochondrial diseases are caused by inherited or acquired mutations in mitochondrial DNA. [0005] For example, mitochondrial function may be altered due to swelling...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/12A61K35/54A61K35/28A61K9/00
CPCA61K9/00A61K35/12A61K35/28A61K35/54A61P9/10A61P21/00A61K35/50
Inventor 崔容秀尹畅九金美真黄晶煜
Owner PAEAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com